IL12B , IL23A , IL23R and HLA-C*06 genetic variants in psoriasis susceptibility and response to treatment
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Human Immunology
- Vol. 79 (4) , 213-217
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Polymorphisms inCD84,IL12BandTNFAIP3are associated with response to biologics in patients with psoriasisBritish Journal of Dermatology, 2017
- The role of IL 23 in the treatment of psoriasisExpert Review of Clinical Immunology, 2017
- IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in PsoriasisDermatology, 2015
- The immunogenetics of Psoriasis: A comprehensive reviewJournal of Autoimmunity, 2015
- Genetic and epigenetic basis of psoriasis pathogenesisMolecular Immunology, 2015
- Clinical improvement in psoriasis with specific targeting of interleukin-23Nature, 2015
- Geoepidemiology and environmental factors of psoriasis and psoriatic arthritisJournal of Autoimmunity, 2010
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk GenesThe American Journal of Human Genetics, 2007
- Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8+ T cellsClinical and Experimental Immunology, 2004